Antibody-Mediated Suppression of Antiviral Inflammasome Activation

抗体介导的抗病毒炎症小体激活抑制

• 批准号: 8602548
• 负责人: ANDREA L COX
• 金额: $ 45.57万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-07-03 至 2018-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8602548
• 关键词: Age; Antibodies; Antiviral Agents; Atherosclerosis; Binding; Biological Assay; Biological Models; Blocking Antibodies; Cardiovascular Diseases; Cardiovascular Models; Characteristics; Chronic; Chronic Hepatitis C; Chronic Kidney Failure; Complement; Complex; Data; Development; Diabetes Mellitus; Disease; Endocytosis; Endotoxins; Excision; Fc Immunoglobulins; Functional disorder; Generations; Goals; HIV; HIV Infections; HIV envelope protein; HIV-1; Heart; Heart Diseases; Hepatitis C; Hepatitis C virus; Highly Active Antiretroviral Therapy; Human; Image; Immune; Immune response; Immunoglobulin Constant Region; Immunologic Receptors; Incidence; Individual; Infection; Infectious Agent; Inflammation; Inflammatory; Interleukin-18; Interleukins; Kidney; Kidney Diseases; Link; Liver; Liver diseases; Malignant Neoplasms; Measures; Mediating; Medical; Morbidity - disease rate; Organ; Osteoporosis; Pathogenesis; Pathology; Pathway interactions; Patients; Pattern; Phagocytosis; Plasma; Process; Proteins; RNA Viruses; Relative (related person); Renal Glycosuria; Risk; Role; SIV; Sepsis; Serum; Signal Transduction; Small Interfering RNA; Specificity; Stimulus; Surface; Testing; United States; Viral; Virion; Virus; Virus Diseases; base; cytokine; env Gene Products; glycosylation; improved; liver inflammation; macrophage; microbial; monocyte; mortality; neutralizing antibody; new therapeutic target; novel; pathogen; prevent; protein complex; public health relevance; receptor; response; viral RNA

DESCRIPTION: While HAART has reduced the incidence of HIV-related morbidity and mortality, increasing evidence suggests that chronic inflammatory medical illnesses, including cardiovascular disease, diabetes mellitus, chronic kidney and liver disease, osteoporosis, and cancer occur more frequently and/or at earlier ages in HIV infected individuals. Chronic HCV is similarly associated with liver inflammation and increased risk of diabetes mellitus, kidney disease, and cancer. HIV co-infection with HCV results in enhanced progression of inflammation-linked liver and kidney pathology relative to HCV infection alone. However, the pathogenesis of HIV-1 and HCV-related chronic inflammation is complex and incompletely understood. Inflammation in infection is orchestrated by innate immune cell signaling receptors that detect microbial molecules. A subset of intracellular immune receptors can assemble into multi-protein complexes called "inflammasomes". Inflammasomes integrate two pathogen-triggered signaling cascades (signal 1 and 2), ultimately leading to secretion of the active, mature forms of the pro-inflammatory cytokines interleukin (IL)-18 and IL-1¿. Elevated serum IL-18 levels are associated with diabetes, with kidney disease and liver inflammation, and with increased atherosclerosis progression. We recently discovered that HIV and HCV virions assemble inflammasomes in monocytes and macrophages and that a subset of antibodies directed against envelope proteins from either virus can prevent monocyte IL-18 and IL-1¿ release in response to cognate virus. The mechanism through which antibodies specific for HIV or HCV prevent activation of the inflammasome by cognate virus and what antibody characteristics are critical for the process are unknown. Given the increased rates of inflammatory diseases in HIV infected people, our overall goal is to improve our understanding of mechanisms of inflammasome suppression to enhance control of HIV-associated inflammation. In Aim 1, we will test whether co-infection increases inflammasome activation relative to monoinfection by comparing IL-18, IL-1¿, and other proinflammatory cytokine levels in plasma from HIV infected, HCV infected, HIV/HCV co-infected, and uninfected subjects. Using a novel model system, we will assess the effect of HIV and HCV specific-antibodies on monocyte inflammasome activation with both viruses present. In Aim 2, we will determine if envelope antibodies block one or both signals in the pathogen-triggered signaling cascades and correlate the degree of inflammasome inhibition to inhibition of the two signals. In Aim 3, we will determine the role of the constant region (Fc) of anti-envelope antibodies in inflammasome inhibition. These studies will break new ground by revealing mechanisms of stimulation and modulation of inflammation triggered by chronic viruses, potentially explaining increased inflammation of the liver, kidney, and other organs and providing new therapeutic targets for modulation of that inflammation.

产品说明：虽然HAART降低了HIV相关发病率和死亡率，但越来越多的证据表明，慢性炎症性医学疾病，包括心血管疾病、糖尿病、慢性肾脏和肝脏疾病、骨质疏松症和癌症，在HIV感染者中发生得更频繁和/或发生在更早的年龄。慢性HCV与肝脏炎症和糖尿病、肾脏疾病和癌症的风险增加类似。相对于单独的HCV感染，HIV与HCV合并感染会导致炎症相关的肝脏和肾脏病理的进展加快。然而，HIV-1和HCV相关的慢性炎症的发病机制是复杂的和不完全理解。感染中的炎症是由检测微生物分子的先天免疫细胞信号受体协调的。细胞内免疫受体的子集可以组装成称为“炎性体”的多蛋白质复合物。炎性小体整合了两个病原体触发的信号级联（信号1和2），最终导致促炎细胞因子白细胞介素（IL）-18和IL-1的活性成熟形式的分泌。血清IL-18水平升高与糖尿病、肾脏疾病和肝脏炎症以及动脉粥样硬化进展增加相关。我们最近发现，HIV和HCV病毒粒子在单核细胞和巨噬细胞中组装炎性体，并且针对来自任一病毒的包膜蛋白的抗体子集可以阻止单核细胞响应于同源病毒而释放IL-18和IL-1？。HIV或HCV特异性抗体阻止同源病毒激活炎性小体的机制以及该过程的关键抗体特征尚不清楚。鉴于HIV感染者炎症性疾病的发病率增加，我们的总体目标是提高我们对炎性小体抑制机制的理解，以加强对HIV相关炎症的控制。在目标1中，我们将通过比较HIV感染者、HCV感染者、HIV/HCV共感染者和未感染者血浆中的IL-18、IL-1？和其他促炎细胞因子水平，来测试共感染是否相对于单一感染增加炎性小体活化。使用一种新的模型系统，我们将评估HIV和HCV特异性抗体对两种病毒存在的单核细胞炎性小体激活的影响。在目标2中，我们将确定包膜抗体是否阻断病原体触发的信号级联中的一个或两个信号，并将炎性小体抑制的程度与两个信号的抑制相关联。在目标3中，我们 确定抗包膜抗体的恒定区（Fc）在炎性小体抑制中的作用。这些研究将通过揭示慢性病毒引发的炎症刺激和调节机制来开辟新天地，可能解释肝脏，肾脏和其他器官的炎症增加，并为炎症调节提供新的治疗靶点。